Facioscapulohumeral Muscular Dystrophy (FSHD) — Comprehensive Research Report

1. Disease Information

Overview: Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant, progressive skeletal myopathy classically characterized by weakness beginning in the facial muscles, muscles stabilizing the scapula (periscapular/shoulder girdle), and foot dorsiflexors, with later, often asymmetric, involvement of the trunk, hip girdle, and lower limbs. It is the third most common inherited muscular dystrophy after Duchenne/Becker and myotonic dystrophy. Onset is typically in the first three decades of life (95% show clinical signs before age 20), severity is highly variable (even within families), progression is slow but steady, and life expectancy is generally not shortened, although up to ~20–24% of affected individuals eventually require wheelchair use (GeneReviews; 5-year natural history study, PMID:39508285).

Key identifiers: - OMIM: #158900 (FSHD1), #158901 (FSHD2, digenic) - MONDO: MONDO:0001347 (disease umbrella); FSHD1/FSHD2 subtypes are separately mapped in MONDO/OMIM - ICD-10-CM: G71.02 (Facioscapulohumeral muscular dystrophy), under G71.0 (Muscular dystrophy) - ICD-11: 8C70.3 - Disease Ontology: DOID:11727 (FSHD), DOID:0111192 - MeSH: D020391 (Muscular Dystrophy, Facioscapulohumeral) - Orphanet: ORPHA:269 (FSHD), with ORPHA:2044/369 for FSHD1/FSHD2 subtypes

Synonyms: Landouzy-Dejerine muscular dystrophy; FSHD; facioscapulohumeral dystrophy (FSHMD).

Evidence source note: Most information below derives from aggregated disease-level resources (OMIM, GeneReviews, Orphanet), large clinical cohort/registry studies (French, Italian, Dutch, US national registries), and primary molecular/cell-biology literature — individually cited by PMID where possible; a smaller subset (mouse/zebrafish models) is model-organism evidence, explicitly flagged.

Sources: GeneReviews — FSHD · OMIM #158900 · OMIM #158901 · NORD · ICD10Data G71.02

2. Etiology

Disease causal factors — genetic, chromatin-based mechanism

FSHD is fundamentally a chromatin-derepression disease, not a classic loss-of-function/structural-protein myopathy. Both molecular subtypes converge on the same final pathogenic event: inappropriate somatic expression of the DUX4 retrogene in skeletal muscle.

• FSHD1 (~95% of cases): monoallelic contraction of the D4Z4 macrosatellite repeat array in the subtelomeric region of chromosome 4q35, from the normal 11–150 repeat units down to 1–10 units, occurring specifically on a "permissive" 4qA haplotype that provides a polyadenylation signal (PAS) distal to the last repeat unit, stabilizing the DUX4 transcript.
• FSHD2 (<5% of cases): normal-sized (non-contracted) D4Z4 array but digenic inheritance of (1) a permissive 4qA haplotype in trans, plus (2) a loss-of-function variant in a chromatin-modifier gene — most commonly SMCHD1 (chromosome 18), and less commonly DNMT3B or LRIF1 — that causes genome-wide/D4Z4-specific hypomethylation.

"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2" (Lemmers et al. 2012, PMID:23143600)

• SMCHD1 as a disease-severity modifier in FSHD1: independent of causing FSHD2, hypomorphic SMCHD1 variants can act as a second hit in FSHD1 families, worsening severity when co-inherited with a D4Z4 contraction (Sacconi et al. 2013, PMID:24075187).

Risk factors

• Genetic:
• D4Z4 repeat number is inversely correlated with severity/earlier onset — the shortest arrays (1–3 units) produce infantile/severe disease.
• Reduced-penetrance ("grey zone") alleles of 8–11 repeat units on a permissive haplotype confer variable, epigenetically-modulated penetrance.
• SMCHD1 loss-of-function variants (modifier in FSHD1; causal in FSHD2).
• The non-permissive 4qB haplotype and homologous chromosome 10q35 D4Z4 repeats are not pathogenic even when contracted, because they lack the stabilizing PAS.
• Environmental/demographic: Sex — males are more frequently and more severely affected than females at any given repeat size (a documented sex-modifier effect, mechanism not fully resolved); no clear toxin/occupational/infectious risk factors identified. Age of onset is a marker of severity (earlier onset → more severe course; PMID:30819914 / Neurology 2019 review referenced above).
• Ancestry: Population studies note genetic and haplotype diversity affecting FSHD across ancestries; diagnostic algorithms developed largely in European cohorts under-recognize some non-European allele configurations (J Hum Genet 2025).

Protective factors

• Longer residual D4Z4 arrays (11+ units) on a permissive haplotype are largely non-penetrant.
• Non-permissive 4qB haplotype is protective regardless of repeat number.
• Intact SMCHD1/DNMT3B/LRIF1 function maintaining D4Z4 heterochromatinization is protective against DUX4 de-repression.
• No established pharmacologic/dietary protective factor is validated in humans to date.

Gene–environment interactions

The core "interaction" in FSHD is genetic epistasis rather than classic gene-environment interaction: D4Z4 copy number, haplotype (cis) and SMCHD1/DNMT3B/LRIF1 genotype (trans, modifying chromatin state) jointly determine whether the chromatin permits DUX4 transcription. Muscle-intrinsic stressors (oxidative stress, myogenic differentiation state) modulate DUX4 expression level within a genetically permissive substrate, but there is no established exogenous environmental trigger. Suggested GENO/relationship modeling: SMCHD1 as MODIFIER/SUSCEPTIBILITY in FSHD1 entries; DUX4 (D4Z4-encoded) as the primary causal locus.

Sources: Lemmers 2012, PMID:23143600 · Sacconi 2013, PMID:24075187 · OMIM 158901 · Genetic and Epigenetic Contributors to FSHD, PMC4674299

3. Phenotypes

Progression/severity pattern: Slowly progressive, often asymmetric, "descending" pattern (face → shoulder girdle → trunk/foot dorsiflexors → hip girdle/proximal legs); quantitative muscle strength declines ~1–4%/year on average, with substantial inter-individual variability (5-year natural history, PMID:39508285; Statland 2019 Neurology, early-onset severity marker).

Quality of life impact: Chronic pain, fatigue, and mobility limitation (up to 20–24% requiring wheelchair by disease course) are major drivers of reduced quality of life; facial weakness affects speech/expression and social functioning; scapular winging and shoulder weakness substantially limit overhead activity and activities of daily living.

Sources: Pediatric Review of FSHD, PMC6435288 · Ophthalmologic Manifestations of FSHD — EyeWiki · Retinal vascular disease and hearing loss in FSHD, PMID:23573590 · Longitudinal childhood-onset FSHD, PMC11655134

4. Genetic/Molecular Information

Causal loci: - DUX4 (Double homeobox 4; HGNC:50800), encoded within each D4Z4 repeat unit on chromosome 4q35, subtelomeric. OMIM gene: DUX4, 606009. This is the pathogenic effector gene for both FSHD1 and FSHD2. - D4Z4 repeat array itself (a 3.3-kb macrosatellite, not a conventional gene) — copy number is the causal structural variant in FSHD1. - SMCHD1 (Structural Maintenance of Chromosomes flexible Hinge Domain containing 1; HGNC:29092), chromosome 18p11.32. OMIM 614982. Primary FSHD2 gene; modifier in FSHD1. - DNMT3B (DNA methyltransferase 3 beta; HGNC:2979), chromosome 20q11.21. OMIM 602900. Rare FSHD2 gene. - LRIF1* (Ligand Dependent Nuclear Receptor Interacting Factor 1; HGNC:21470), chromosome 1p13.2. Very rare FSHD2 gene, converges with SMCHD1 at the D4Z4 locus and its own promoter (PMC10307901).

Pathogenic variant classes: - FSHD1: not a point-mutation disease — the pathogenic lesion is a repeat contraction (structural variant), classified/sized by pulsed-field gel electrophoresis (EcoRI fragment size), Southern blot, or optical genome mapping. Contracted alleles of 1–10 units are pathogenic; 8–11 units on a permissive haplotype represent reduced-penetrance "grey zone" alleles. - FSHD2 (SMCHD1/DNMT3B/LRIF1): predominantly loss-of-function variants — nonsense, frameshift, splice-site, and some missense variants disrupting ATPase or hinge domains of SMCHD1 — classified pathogenic/likely pathogenic per ACMG/AMP criteria in ClinVar. - Allele frequency: Because pathogenic D4Z4 contractions are structural/repeat-based, they are not well-represented in standard SNV population databases (gnomAD/1000 Genomes); permissive 4qA vs. non-permissive 4qB/10q-derived haplotype frequencies have been characterized by haplotype-specific genotyping across populations. - Somatic vs. germline: FSHD1 contractions and FSHD2 variants are typically germline (heritable), but somatic mosaicism is common: found in ~40% of de novo FSHD1 families (patient or unaffected parent), often via an intrachromosomal gene-conversion-like mechanism, sometimes involving mitotic interchromosomal exchange between 4q35 and its homologous 10q26 locus (Lemmers 2004, PMID:15174019; van der Maarel 2000, PMID:10631134). Germline mosaicism is also documented and important for recurrence-risk counseling in apparently de novo cases. - Functional consequence: Loss of D4Z4-array heterochromatin repression (FSHD1: reduced unit number reduces chromatin-packing capacity; FSHD2: SMCHD1/DNMT3B/LRIF1 LOF removes the trans-acting silencing machinery) → chromatin opening/hypomethylation → DUX4 gain-of-function (ectopic transcription factor expression) is the shared functional endpoint. This is best framed as a gain-of-function toxic-protein mechanism secondary to an epigenetic derepression event.

Modifier genes: SMCHD1 (in FSHD1), and D4Z4 repeat number itself modifies FSHD2 penetrance/severity (larger residual arrays in FSHD2 patients still require SMCHD1 hypomorphism to permit DUX4 expression).

Epigenetic information: The central epigenetic lesion is loss of D4Z4 CpG methylation and repressive heterochromatin marks (reduced H3K9me3, loss of SMCHD1-dependent chromatin compaction) at the contracted (FSHD1) or SMCHD1-destabilized (FSHD2) D4Z4 array, permitting transcription factor access and stabilized DUX4 mRNA via the distal permissive PAS. DNA-methylation analysis of D4Z4 (bisulfite sequencing) is diagnostically useful, particularly for confirming FSHD2 when repeat size is normal.

Chromosomal context: No aneuploidy/large structural chromosomal abnormality is causal; the key structural feature is the tandem-repeat copy-number variant at 4q35, and the near-identical but non-pathogenic homologous repeat array at 10q26 (a recognized source of diagnostic confusion requiring haplotype-specific testing).

Suggested ontology bindings: gene hgnc:50800 (DUX4), hgnc:29092 (SMCHD1), hgnc:2979 (DNMT3B), hgnc:21470 (LRIF1); GO biological process GO:0006325 (chromatin organization), GO:0006306 (DNA methylation).

Sources: Genetic and Epigenetic Contributors to FSHD, PMC4674299 · SMCHD1/LRIF1 convergence, PMC10307901 · Somatic mosaicism, PMID:15174019 · OMIM 158901

5. Environmental Information

FSHD has no established environmental, toxic, occupational, or infectious causal or triggering factor — it is a monogenic/digenic disease driven entirely by the D4Z4/DUX4 chromatin mechanism above. No lifestyle factor (smoking, diet, alcohol) has been shown to alter disease risk or onset, though general muscle-health lifestyle measures (avoiding disuse, moderate aerobic/resistance exercise under supervision) are recommended as supportive management, not causal-risk mitigation (see Treatment/Prevention). No infectious agent is implicated. This section is largely not applicable for FSHD beyond noting the absence of such factors — a point worth explicitly recording rather than omitting.

6. Mechanism / Pathophysiology

Causal chain (trigger → clinical manifestation):

1. Trigger: D4Z4 repeat contraction (FSHD1) or SMCHD1/DNMT3B/LRIF1 loss-of-function on a background of a normal-length D4Z4 array (FSHD2), both occurring in cis/trans with a permissive 4qA haplotype.
2. Chromatin derepression: Loss of D4Z4 heterochromatin (reduced CpG methylation, reduced repressive histone marks, SMCHD1-dependent chromatin compaction failure) → open chromatin state at the distal D4Z4 unit.
3. Stabilized DUX4 transcription: The permissive 4qA polyadenylation signal stabilizes the DUX4-fl (full-length) transcript, which would otherwise be degraded. Only DUX4-fl (retaining its C-terminal transactivation domain) is transcriptionally active.
4. DUX4 target-gene activation: DUX4 is a double-homeodomain transcription factor that binds and activates a "germline/cleavage-stage embryo" gene program normally restricted to early embryogenesis/zygotic genome activation (e.g., ZSCAN4, PRAMEF1, RFPL2, TRIM43, MBD3L2, KHDC1), plus retroelements (endogenous retroviruses/LINE elements) and innate-immune mediators (Geng 2012, PMID cited in Developmental Cell paper).
5. Cellular toxicity: Because the germline is immune-privileged, aberrant somatic expression of germline-restricted proteins triggers innate immune/dsRNA sensing pathways and MYC-mRNA-stabilization-driven apoptosis (PMID: PLOS Genetics, PMC5362247); DUX4 also increases reactive oxygen species (ROS) and confers susceptibility to oxidative-stress-induced cell death, rescuable by DUX4 knockdown or antioxidants.
6. Muscle-specific consequences: DUX4 globally represses PAX7 target genes, impairing satellite-cell/myogenic regenerative programs (Banerji 2017, PMC5735185); combined with atrophy/protein-degradation gene induction and impaired regeneration, this drives progressive myofiber loss, replacement by fat/fibrosis, and clinical weakness following the characteristic descending facioscapulohumeral distribution.
7. Downstream tissue effects: Chronic muscle degeneration → weakness, scapular winging, contractures; extramuscular DUX4-related or vascular effects → retinal telangiectasia/Coats-like vasculopathy and sensorineural hearing loss (mechanism less well resolved than muscle pathway, possibly reflecting low-level DUX4 expression or vascular developmental sensitivity in cochlea/retina).

Cell types/processes involved: - Skeletal myonuclei (mosaic/sporadic DUX4 expression — only a small fraction of nuclei per myofiber express DUX4 at any time, a hallmark "bursting" expression pattern (CL:0000188 skeletal muscle fiber, CL:0000059/myonuclei more specifically muscle satellite/myogenic lineage: CL:0000515 or CL:0008019 skeletal muscle satellite stem cell for PAX7-related regenerative deficit). - Innate immune signaling (dsRNA sensors, e.g., PKR/interferon pathway) — GO:0060337 (type I interferon signaling), GO:0006915 (apoptotic process). - Retinal vascular endothelium (Coats-like vasculopathy) and cochlear hair cells/stria vascularis (sensorineural hearing loss) — mechanistically less characterized but plausibly linked to low DUX4 expression in these tissues during development.

Protein dysfunction: DUX4 itself functions as a gain-of-function transcriptional activator (not a misfolding/loss-of-function protein); SMCHD1 loss is a loss-of-function chromatin-structural defect (SMCHD1 normally compacts D4Z4 chromatin via its ATPase/hinge domains).

Molecular profiling: Muscle transcriptomic studies (RNA-seq) in FSHD biopsies and myoblast/myotube models show the DUX4-target signature (germline genes, immune genes) as a validated disease biomarker used in clinical trials (e.g., losmapimod trials measured DUX4-driven gene expression as a pharmacodynamic biomarker, though technical variability limited its use as a primary trial endpoint).

Advanced technologies: Single-nucleus/single-cell approaches have shown DUX4 expression occurs in rare, transient "bursts" in a small subset of myonuclei — a key reason bulk transcriptomic DUX4 biomarkers are noisy and difficult to use clinically. CRISPR-based functional screens and engineered SMCHD1/D4Z4 mutant cell/mouse models have been used to dissect the synergy between heterochromatin disruption and DUX4 network feedforward activation (bioRxiv/PMC10951985).

Sources: DUX4 activates germline genes, retroelements, immune mediators — Developmental Cell · DUX4-induced dsRNA/MYC apoptosis, PMC5362247 · PAX7 target gene repression, PMC5735185 · Engineered SMCHD1/D4Z4 mutations, PMC10951985 · DUX4 signalling review, MDPI

7. Anatomical Structures Affected

Organ level: - Primary: skeletal muscle (face, shoulder girdle/scapular stabilizers, upper arm, foot dorsiflexors, later abdominal/trunk and pelvic-girdle muscles). - Secondary: eye (retina — vasculopathy/Coats disease), ear (cochlea — sensorineural hearing loss), lung (restrictive respiratory insufficiency in advanced/wheelchair-dependent disease), rarely CNS (intellectual disability/epilepsy in infantile-onset cases only). - Body systems: musculoskeletal (primary), sensory (auditory, visual), respiratory (secondary/late), rarely neurodevelopmental.

Tissue/cell level: - Skeletal muscle fibers (type-specific vulnerability not sharply established), muscle satellite cells/myogenic progenitors (CL:0008019), retinal vascular endothelium, cochlear sensory/vascular structures.

Subcellular level: - Nucleus (chromatin/heterochromatin at the D4Z4 locus; GO:0000228 nuclear chromosome), site of DUX4 transcriptional activity; mitochondria (oxidative stress/ROS generation — GO:0005739).

Localization (UBERON suggestions): - UBERON:0001630 (muscle organ) — specifically facial muscles (UBERON:0001336 orbicularis oculi / UBERON:0011639 orbicularis oris region), UBERON:0006611 (scapular musculature) or specific muscles (trapezius, serratus anterior, rhomboids), UBERON:0001383 (tibialis anterior/dorsiflexor compartment). - UBERON:0000966 (retina) for Coats-like vasculopathy. - UBERON:0001846 (cochlea) for sensorineural hearing loss.

Lateralization: A hallmark distinguishing clinical feature is asymmetric weakness — unlike most other muscular dystrophies, FSHD often shows notably asymmetric involvement between left and right sides, even within the same muscle group.

Sources: EyeWiki — Ophthalmologic Manifestations of FSHD · Medscape FSHD Clinical Presentation

8. Temporal Development

Onset: - Typical: first–third decade of life; 95% show clinical signs before age 20 (childhood/adolescent-to-young-adult onset is most common presentation, though subclinical facial weakness may predate recognized symptoms). - Infantile-onset FSHD: a distinct, more severe subset presenting as early as infancy (case reports of symptom onset by 5 months of age), strongly associated with very short D4Z4 arrays (1–3 units, EcoRI fragment 10–14 kb) (Timely Review, PMC7589635). - Onset pattern: insidious/gradual in classic FSHD; more rapid and multisystemic in infantile-onset disease.

Progression: - Disease course: chronic, slowly progressive; classic "descending" spatial pattern — face → shoulder girdle/scapular stabilizers → upper arm → trunk/foot dorsiflexors → hip girdle/proximal lower limb. - Progression rate: quantitative muscle strength declines at an average ~1–4%/year, but highly variable between individuals and even between muscle groups in the same patient; 6-year cumulative risk of wheelchair dependence estimated at ~24% in one longitudinal cohort (5-year natural history study, PMID:39508285). - Disease duration: chronic, lifelong; not typically self-limited or remitting. - Infantile FSHD: rapid decline, marked muscle wasting, more prominent extramuscular (hearing, retinal, occasionally CNS) involvement.

Patterns: - No spontaneous or treatment-induced remission is described — FSHD is a monotonic, progressive (though slow and plateau-punctuated) disease. - Critical/vulnerable periods: earlier age of onset is itself a validated marker of eventual disease severity, making early recognition clinically important for prognostication and counseling (rather than for a treatable "window").

Sources: Longitudinal childhood-onset FSHD 5-year study, PMC11655134 · Early onset as marker for severity, Neurology 2019 · Early-Onset Infantile FSHD Review, PMC7589635

9. Inheritance and Population

Epidemiology: - Prevalence estimates vary by methodology: ~3.2–4.6 per 100,000 in several population studies; US estimate ~1 in 20,000; broader worldwide estimates of 4–10 per 100,000. - Incidence: conservative estimate ~1 in 14,286 births; with improved genetic testing and ascertainment, some estimate a true incidence closer to 1 in 7,500 births. - Recognized as the third most common muscular dystrophy overall.

Inheritance pattern: - FSHD1: autosomal dominant (single contracted D4Z4 allele on a permissive haplotype is sufficient). - FSHD2: digenic — autosomal dominant SMCHD1 (or DNMT3B/LRIF1) variant combined with a permissive 4qA haplotype in trans (inherited independently; both are required for disease expression) — a well-characterized digenic inheritance exemplar (OMIM #158901). - Penetrance: Generally high but genotype-dependent; incomplete/age- and epigenetically-dependent penetrance in the 8–11 unit "grey zone" alleles. Overall clinical penetrance by age 30 is estimated around 95% for classic contracted alleles, but is lower and more variable for borderline-sized alleles. - Expressivity: Markedly variable expressivity, even within the same family carrying an identical D4Z4 contraction — a defining feature of FSHD, attributed to superimposed epigenetic/stochastic DUX4-expression variability and modifier loci (e.g., SMCHD1 second hits). - Genetic anticipation: Not a classic anticipation disease (unlike CTG-repeat disorders), though intergenerational contraction-size instability of D4Z4 can occur. - Germline and somatic mosaicism: Both are well documented; somatic mosaicism found in ~40% of de novo FSHD1 families; mosaic males are typically clinically affected while mosaic females are more often unaffected carriers/parents of a nonmosaic de novo child (a notable sex-dependent asymmetry) (van der Maarel 2000, PMID:10631134). - Founder effects: Not a major feature; permissive-haplotype (4qA) frequency and specific haplotype subtypes vary by ancestry, contributing to some population-level diagnostic complexity (J Hum Genet 2025). - Consanguinity: Not a notable risk factor given the dominant/digenic (not recessive) inheritance. - Carrier frequency: Population frequency of the permissive 4qA haplotype itself is common in the general population (a large fraction of people carry a permissive haplotype without ever having a pathogenic contraction), underscoring that haplotype alone is necessary but not sufficient.

Population demographics: - No strong racial/ethnic predilection reported, though data ascertainment has historically skewed European; diversity studies are ongoing. - Sex ratio: males more frequently and more severely affected than females at a given genotype (asymptomatic carriage more common in females) — a recognized but mechanistically unresolved sex-modifier effect. - Age distribution: broad, spanning infantile to adult-onset; most clinically recognized cases present in childhood through young adulthood.

Sources: Wellstone Program — FSHD Facts and Statistics · Medscape — FSHD Epidemiology · Diversity challenges genetics in FSHD, J Hum Genet 2025 · OMIM #158901

10. Diagnostics

Clinical tests / exam: - Clinical diagnosis rests on the characteristic pattern of facial, scapular-stabilizer, and foot-dorsiflexor weakness with typical asymmetry. - Creatine kinase (CK): typically normal to mildly elevated (2–5× ULN), distinguishing FSHD from dystrophinopathies where CK is markedly elevated. - EMG: myopathic pattern (nonspecific). - Muscle MRI: identifies pattern and degree of fatty infiltration/edema in affected muscles, increasingly used for phenotyping and clinical-trial outcome assessment (quantitative MRI fat-fraction as a biomarker). - Muscle biopsy: nonspecific dystrophic changes; historically used before molecular testing became standard, now largely reserved for atypical presentations.

Genetic testing (primary diagnostic modality): - FSHD1: Molecular confirmation via Southern blot with EcoRI/EcoRI-BlnI digestion (measuring D4Z4 repeat/EcoRI fragment size) or newer techniques — optical genome mapping has been validated as an accurate, higher-throughput alternative for sizing D4Z4 alleles and determining 4qA/4qB haplotype (PMC10664978; PMC10743191). - Haplotype analysis: visual genotyping / multiplex dipstick assays distinguish the permissive 4qA vs. non-permissive 4qB/10q-derived haplotypes — essential because a short array on a non-permissive haplotype is not pathogenic. - FSHD2: diagnosed when a patient has classic clinical features, a normal-sized D4Z4 array on a permissive 4qA haplotype, and D4Z4 hypomethylation on bisulfite/methylation analysis — followed by sequencing of SMCHD1 (first-line), then DNMT3B/LRIF1 if SMCHD1-negative. - Long-read genome sequencing and rare-variant linkage analysis have also been used for complex/ambiguous cases (medRxiv 2023.06.05.23290975). - Chromosomal microarray, karyotyping, FISH, and mitochondrial DNA testing are not primary diagnostic tools for FSHD (the causal lesion is a repeat-array size/methylation change, not aneuploidy or a point variant detectable by standard panels).

Clinical diagnostic criteria: No formal DSM/consensus scoring system analogous to other diseases; diagnosis is established per GeneReviews criteria combining clinical phenotype + molecular confirmation (repeat size + haplotype for FSHD1; methylation + SMCHD1/DNMT3B/LRIF1 sequencing for FSHD2). An AAN practice guideline exists for evaluation, diagnosis, and management (AAN Guideline).

Differential diagnosis: Limb-girdle muscular dystrophies, myotonic dystrophy, congenital myopathies, mitochondrial myopathies, polymyositis/inflammatory myopathy (facial-sparing usually distinguishes these), and other scapuloperoneal syndromes.

Screening: No population-based newborn screening program exists for FSHD (unlike some other genetic muscular dystrophies); genetic counseling and cascade testing of at-risk relatives is standard once a proband is confirmed, given autosomal dominant/digenic inheritance and variable/incomplete penetrance in grey-zone alleles.

Sources: Optical genome mapping validation, PMC10664978 · Molecular diagnosis review — ScienceDirect · GeneReviews FSHD · AAN FSHD Guideline

11. Outcome/Prognosis

Survival/mortality: Life expectancy is generally not shortened in classic FSHD; it is considered a disease of morbidity rather than mortality, distinguishing it from many other muscular dystrophies (e.g., Duchenne). Infantile-onset/very-severe cases with major respiratory or CNS complications may carry somewhat worse prognoses, but disease-specific mortality data are limited.

Morbidity/function: - Up to ~20–24% of patients become wheelchair-dependent over the disease course (6-year cumulative risk ~24% in one cohort). - Progressive weakness affects mobility, upper-limb function (especially overhead reaching due to scapular winging), facial expression/speech, and — in a minority — respiratory function in advanced disease. - Chronic pain and fatigue are prominent, underrecognized contributors to reduced quality of life, frequently reported in patient registry studies.

Disease course/complications: Retinal Coats-disease-related vision loss (rare but serious, more common in early-onset/severe genotypes), sensorineural hearing loss, contractures, and (in advanced disease) restrictive respiratory insufficiency requiring monitoring/ventilatory support.

Prognostic factors: D4Z4 repeat array size is the strongest genotype-phenotype correlate — shorter arrays (fewer repeat units) predict earlier onset and more severe, faster-progressing, more extramuscularly-involved disease; age of onset itself is an independent severity marker (earlier onset correlates with worse ultimate outcome). SMCHD1 modifier status in FSHD1 patients further worsens prognosis.

Prognostic biomarkers: DUX4-driven target-gene expression signatures and muscle MRI fat-fraction/STIR-hyperintensity have been explored as biomarkers of disease activity and progression risk, used in recent clinical trials (though with technical reproducibility challenges).

Sources: 5-year natural history cohort, PMID:39508285 · Italian National Registry 5-year follow-up, PMC7815626 · Early onset as severity marker, Neurology 2019

12. Treatment

Current standard of care is supportive — there is no FDA-approved disease-modifying therapy for FSHD as of mid-2026.

Pharmacotherapy: - No approved DUX4-targeted or disease-modifying drug. Symptomatic management includes analgesics for chronic pain and standard supportive medications; no established pharmacogenomic guidance specific to FSHD. - Losmapimod (p38α/β MAPK inhibitor; indirectly reduces DUX4 program activation without impairing myogenesis) — showed encouraging Phase 2b (ReDUX4) results (slowed structural/functional disease progression at 48 weeks), but the confirmatory Phase 3 REACH trial (NCT04003974) reported topline results on Sept 12, 2024 that did not meet its primary endpoint (Reachable Workspace change) or achieve nominally significant secondary endpoints; Fulcrum Therapeutics subsequently suspended the losmapimod FSHD program (Fulcrum press release, Sept 2024; NeurologyLive coverage).

Advanced/RNA-based therapeutics in development (not yet approved): - Direct DUX4 mRNA knockdown — antisense oligonucleotides (ASOs)/gapmers: preclinical work (2′MOE and LNA-chemistry gapmers) shows effective DUX4 knockdown and improved muscle function (grip strength) in mouse models via subcutaneous dosing (PMC12795667; systemic ASO delivery, PMC8526479). Companies pursuing direct DUX4-targeting approaches include Dyne Therapeutics, Avidity Biosciences, Arrowhead Pharmaceuticals, and miRecule. - AOC 1020 (Avidity Biosciences) — an antibody-oligonucleotide conjugate targeting DUX4, evaluated in the Phase 1/2 FORTITUDE trial (NCT05747924), with a Phase 3 trial in the pipeline as of 2025–2026 as a step toward potential FDA approval. - Follistatin/myostatin-pathway (muscle-growth-promoting) approach — ACE-083 (Acceleron): a locally-injected follistatin-based agent that increased target muscle volume in a Phase 2 trial but did not translate to improved function, leading to discontinuation of that program for FSHD (Statland et al. 2022, Muscle & Nerve, PMID via search). - Gene therapy/CRISPR-based epigenetic silencing approaches (targeting DUX4 locus re-repression, e.g., via engineered zinc-finger or CRISPR-dCas9 epigenetic editors) and further AAV-delivered shRNA approaches are in earlier preclinical stages; a 2025 mouse study found AAV-shDUX4 provided only short-term benefit with waning long-term efficacy due to muscle regeneration diluting AAV genomes (Molecular Therapy Methods & Clinical Development 2025).

Surgical/interventional: - Scapular fixation/fusion surgery — stabilizes the winging scapula to the rib cage (bone graft fusion or screw/wire fixation), improving functional leverage for arm use in appropriately selected patients, performed by surgeons experienced with FSHD; decreases scapular rotation range but often nets functional benefit for overhead/reaching tasks (NCIT:C15329 Surgical Procedure / more specific orthopedic procedure term).

Supportive/rehabilitative: - Physical and occupational therapy focused on maintaining function and preventing contractures/disuse atrophy (rather than restorative rehab); orthoses (e.g., ankle-foot orthoses for foot drop); moderate, individualized aerobic/strength exercise programs under specialist supervision (research ongoing on optimal, safe exercise protocols); respiratory therapy/monitoring for advanced disease; low-vision/audiology support for extramuscular retinal/hearing complications; ophthalmologic screening and, when needed, laser photocoagulation or anti-VEGF therapy (e.g., ranibizumab) for Coats-disease-related retinal vasculopathy.

Experimental/clinical trials: Numerous active trials registered at ClinicalTrials.gov beyond those above, including natural history/outcome-measure studies (e.g., NCT04369209 registered cohort) and shoulder-instability mechanism studies (NCT05239520).

Treatment strategy: Multidisciplinary care (neurology, physiatry/PT-OT, orthopedic surgery, ophthalmology, audiology, pulmonology, genetic counseling) is the current mainstay; no genotype-guided personalized pharmacotherapy yet exists, though D4Z4 size/SMCHD1 status informs prognosis and eligibility for genotype-restricted (e.g., FSHD1-only) trials such as REACH.

Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy, for losmapimod/investigational agents) with therapeutic_modality: SMALL_MOLECULE; NCIT:C15238 (Gene Therapy) / ANTISENSE_OLIGONUCLEOTIDE modality for DUX4-targeted ASOs/AOC 1020; NCIT:C15329 or C16186 (Orthopedic Surgical Procedure) for scapular fixation; NCIT:C15302 (Physical Therapy).

Sources: Fulcrum REACH topline results · ACE-083 Phase 2, Statland 2022 · AOC 1020 FORTITUDE trial, NCT05747924 · Current landscape management review, PMC12287641 · ASO gapmer DUX4 knockdown, PMC12795667

13. Prevention

Primary prevention: Not applicable in the traditional sense (no modifiable environmental cause to eliminate); the closest analog is reproductive/genetic prevention via genetic counseling and prenatal or preimplantation genetic diagnosis (PGD) for known-carrier families, given autosomal dominant/digenic inheritance.

Secondary prevention (early detection): Cascade genetic testing of at-risk relatives once a proband is molecularly confirmed; given variable/incomplete penetrance especially for grey-zone (8–11 unit) alleles, early molecular diagnosis allows anticipatory monitoring (audiology, ophthalmology, pulmonary function) before symptom onset, particularly relevant for early-onset/short-repeat genotypes at higher risk of extramuscular complications.

Tertiary prevention: Ophthalmologic screening and monitoring to catch and treat retinal vasculopathy before progression to Coats-disease-related vision loss; audiologic monitoring for hearing loss; proactive physical therapy/orthotic management and periodic pulmonary function assessment to reduce complications of progressive weakness (contractures, falls, respiratory insufficiency) in more advanced disease.

Immunization: Not disease-specific (standard care includes ensuring routine immunizations, including respiratory pathogens, are up to date in patients with any respiratory muscle compromise, but this is generic supportive care, not FSHD-specific prophylaxis).

Genetic counseling: Central to FSHD family management — addressing the autosomal dominant (FSHD1) or digenic (FSHD2) inheritance pattern, variable expressivity, incomplete penetrance of grey-zone alleles, and both somatic and germline mosaicism (which affects recurrence-risk estimates for apparently de novo cases — a parent with somatic/germline mosaicism can have a higher-than-expected recurrence risk for future children despite testing negative on peripheral blood).

Public health/behavioral: No population-level public-health intervention exists (rare monogenic disease); individualized behavioral guidance centers on maintaining physical activity/muscle conditioning within safe limits and fall-prevention strategies as weakness progresses.

Sources: GeneReviews FSHD — Genetic Counseling section · Germinal mosaicism in FSHD, Upadhyaya 1995

14. Other Species / Natural Disease

FSHD is a human-specific molecular disease in a strict sense: the pathogenic DUX4 retrogene and its D4Z4 macrosatellite array, along with the specific 4qA permissive haplotype/polyadenylation signal architecture, are primate/human-specific genomic features. There is no well-characterized naturally occurring FSHD-equivalent disease in veterinary species (dogs, cats, livestock) analogous to, for example, canine dystrophin-deficient muscular dystrophy models for DMD. DUX-family genes exist across mammals (e.g., mouse Dux, expressed during zygotic genome activation), providing evolutionary/developmental-biology context for DUX4's normal role, but these orthologs are not linked to a spontaneous disease phenotype in the source species. This section is therefore largely not applicable, beyond noting the evolutionary conservation of the DUX-family developmental gene-activation role (relevant to model organism engineering, below) rather than any natural veterinary disease counterpart.

Suggested taxonomy note: NCBITaxon:9606 (Homo sapiens) is the sole natural host species for the clinical disease.

15. Model Organisms

Because FSHD's pathogenic mechanism (DUX4 gain-of-function via loss of D4Z4 repeat-mediated silencing) has no natural non-human counterpart, all animal models are engineered/induced, generally via transgenic or conditional expression of human DUX4:

• Mouse models (multiple engineered lines):
• FLExDUX4 — a widely used Cre-inducible, floxed DUX4-full-length conditional transgenic mouse, allowing tunable, tissue- and time-restricted DUX4 expression to titrate pathology severity and avoid the developmental lethality of constitutive DUX4 expression (PMC5802938).
• iDUX4pA and related "TIC-DUX4" inducible models — considered to come closest to recapitulating both clinical (muscle weakness, histopathology) and molecular (DUX4 target-gene activation) features of human FSHD; used as the basis for testing follistatin gene therapy (AAV-follistatin improved functional outcomes in TIC-DUX4 mice — JCI Insight) and AAV-shDUX4 knockdown approaches (Molecular Therapy Methods & Clinical Development 2025).
• Newer transgenic mouse models specifically for investigating human DUX4 expression continue to be developed (2025 bioRxiv report).

• Genetic models available include conditional/inducible transgenics (Cre-lox systems); classic knockout models are not applicable since FSHD is a gain-of-function disease, not a loss-of-function one for DUX4 itself (though SMCHD1 knockout/knock-in mouse models are used to study the FSHD2 chromatin-modifier mechanism).

• Zebrafish model: A transgenic zebrafish DUX4-misexpression model demonstrated that an induced early-developmental burst of DUX4 produces FSHD-like phenotypes emerging later in adulthood, even after DUX4 is no longer detectable — supporting a developmental-origin hypothesis for at least part of FSHD pathogenesis, distinct from purely adult muscle-toxicity mechanisms (Hum Mol Genet 2018, PMID:30307508).

• Cellular/in vitro models: Patient-derived myoblast/myotube cultures (including immortalized FSHD1/FSHD2 patient lines) are the mainstay for mechanistic and drug-screening studies (e.g., losmapimod's selective inhibition of the DUX4 program without impairing myogenesis was demonstrated in FSHD myotube cultures). iPSC-derived myogenic models are increasingly used for genotype-specific (grey-zone allele, SMCHD1-variant) disease modeling.

Model characteristics/limitations: Because DUX4 expression is mosaic, transient/"bursting," and cytotoxic even at low levels, constitutive whole-body DUX4 mouse models are frequently embryonic lethal or severely runted — necessitating the conditional/inducible systems above to titrate expression to sub-lethal, disease-relevant levels. No current animal model fully recapitulates the human D4Z4 repeat-contraction genetics (mice lack a directly homologous D4Z4/DUX4 locus with the human-specific permissive-haplotype architecture), so all models rely on transgenic human DUX4 insertion rather than an endogenous orthologous mutation — an important translational caveat (a candidate HUMAN_MODEL_MISMATCH consideration for any dismech entry: whether mouse/zebrafish DUX4-overexpression phenotypes faithfully model the graded, chronic, mosaic-expression human disease process).

Applications: These models are used to study DUX4-driven transcriptional/apoptotic pathways, test DUX4-suppression therapeutics (ASOs, small molecules, gene therapy), and assess the developmental-origin hypothesis of FSHD pathogenesis.

Sources: FLExDUX4 mouse model, PMC5802938 · AAV-follistatin in TIC-DUX4 mice, JCI Insight · AAV-shDUX4 mouse model 2025 · Transgenic zebrafish DUX4 model, PMID:30307508 · Transgenic mouse models 2025, bioRxiv

Summary of Key Evidence Gaps / Notes for Curation

• Not applicable / no data: environmental/infectious causal factors, veterinary/natural-disease counterparts, cardiac involvement is debated/minor (unlike other dystrophies), no approved disease-modifying pharmacotherapy or gene therapy as of this writing (mid-2026).
• High-confidence, well-cited mechanistic core: D4Z4 contraction/SMCHD1-DNMT3B-LRIF1 chromatin derepression → stabilized DUX4-fl transcription → germline/immune gene program activation → apoptosis/oxidative stress + PAX7-regenerative-program repression → progressive myofiber loss — suitable as the spine of a pathophysiology causal chain, with conforms_to candidacy against no existing dismech module (a novel DUX4-chromatin-derepression mechanism, potentially a future module given its shared logic with other repeat/epigenetic-derepression diseases).
• Active clinical trial landscape (rapidly moving target): losmapimod program discontinued (Sept 2024, Phase 3 miss); ASO/AOC-based DUX4-knockdown programs (AOC 1020/Avidity FORTITUDE, plus Dyne/Arrowhead/miRecule preclinical-to-early-clinical programs) are the most active current therapeutic frontier — recommend periodic re-verification of trial status (NCT05747924 and successors) given the pace of change.
• Digenic inheritance model: FSHD2 is a strong, well-documented exemplar for the dismech digenic/oligogenic inheritance pattern (HP:0010984), directly relevant to the Digenic_and_Oligogenic_Disorders grouping referenced in project conventions.